Lavior Pharma, a woman-owned leader in the pharmaceutical industry dedicated to advancing innovative therapies for chronic and acute wound conditions, announced the promotion and appointment of Daniel Kim as Vice President of Sales for the Asia Pacific market. In this newly created role, Mr. Kim will spearhead Lavior Pharma’s commercial expansion across Asia Pacific, driving the next phase of international growth and reinforcing the company’s mission to improve patient outcomes and quality of life through innovation in wound care.
Health Technology Insights: HOPE Therapeutics Acquires Stake in Cohen and Associates
“In the past two years, Daniel has served as Head of Asia, and his exemplary work ethic, commitment, and outstanding achievements have laid the foundation for our accelerated growth in the region,” said Gilad Savion, CEO of Lavior Pharma. “Appointing him to this key leadership position is the natural next step to propel our mission forward.”
Health Technology Insights: Dario and GreenKey Partner to Transform Sleep Health Nationwide
“Daniel brings over 20 years of leadership in the medical device industry, with an exceptional track record of cultivating distributor partnerships and driving revenue growth across Asia,” said Anabelle Savion, Co-Founder and COO of Lavior Pharma. “His strategic vision and deep market insights will be instrumental as we expand our footprint and deliver cutting-edge wound-care solutions throughout the region.”
Mr. Kim has held senior business development and sales roles at Dentium Europe, Alpha Bio Tec, and CGBIO, consistently exceeding revenue targets and forging strategic distributor alliances across Asia Pacific. His proven ability to identify emerging market trends and tailor go-to-market strategies will be invaluable as Lavior Pharma introduces its novel diabetic foot ulcer and chronic wound-healing therapies to key markets.
“I am honored to take on this expanded role at such a pivotal moment,” said Daniel Kim. “Lavior Pharma’s groundbreaking science and patient-centric approach align perfectly with my passion for expanding access to innovative therapies. I look forward to collaborating with our regional partners and healthcare professionals to transform wound-care standards and improve lives across the Asia Pacific Region.”
This strategic appointment underscores Lavior Pharma’s commitment to accelerated growth in Asia Pacific and its broader vision to transform wound healing worldwide. Under Mr. Kim’s leadership, the company will scale its commercial infrastructure, deepen distributor and hospital networks, and launch targeted educational initiatives to support clinicians and patients.
Health Technology Insights: Lipocine Doses First Patient in Phase 3 LPCN 1154 Trial
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
